Vertex announces positive results from pivotal trials of vanzacaftor/tezacaftor/deutivacaftor, next-in-class triple combination treatment for cystic fibrosis

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced positive results from its once-daily vanzacaftor/tezacaftor/deutivacaftor (the “vanza triple”) program, the most comprehensive phase 3 pivotal program ever conducted by vertex for the treatment of cystic fibrosis (cf), a progressive, multi-organ disease caused by dysfunction of the cftr protein. the phase 3 program included two randomized, double-blind, active-controlled, 52-week trials, skyline 102 and.
VRTX Ratings Summary
VRTX Quant Ranking